82 related articles for article (PubMed ID: 15217956)
1. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956
[TBL] [Abstract][Full Text] [Related]
2. The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 expression.
Rabinovich GA; Rubinstein N; Matar P; Rozados V; Gervasoni S; Scharovsky GO
Cancer Immunol Immunother; 2002 Jan; 50(11):597-603. PubMed ID: 11807623
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice.
Alyamkina EA; Dolgova EV; Likhacheva AS; Rogachev VA; Sebeleva TE; Nikolin VP; Popova NA; Orishchenko KE; Strunkin DN; Chernykh ER; Zagrebelniy SN; Bogachev SS; Shurdov MA
Genet Vaccines Ther; 2009 Aug; 7():12. PubMed ID: 19682353
[TBL] [Abstract][Full Text] [Related]
4. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
[TBL] [Abstract][Full Text] [Related]
5. Myeloid cell leukemia-1: a formidable barrier to anticancer therapeutics and the quest of targeting it.
Sulkshane P; Teni T
Explor Target Antitumor Ther; 2022; 3(3):278-296. PubMed ID: 36045907
[TBL] [Abstract][Full Text] [Related]
6. Dodging the bullet: therapeutic resistance mechanisms in pediatric cancers.
Shah N
Cancer Drug Resist; 2019; 2(3):428-446. PubMed ID: 35582583
[TBL] [Abstract][Full Text] [Related]
7. Elevated USP9X drives early-to-late-stage oral tumorigenesis via stabilisation of anti-apoptotic MCL-1 protein and impacts outcome in oral cancers.
Sulkshane P; Pawar SN; Waghole R; Pawar SS; Rajput P; Uthale A; Oak S; Kalkar P; Wani H; Patil R; Nair S; Rane P; Teni T
Br J Cancer; 2021 Aug; 125(4):547-560. PubMed ID: 34079080
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression.
Omori T; Tazawa H; Yamakawa Y; Osaki S; Hasei J; Sugiu K; Komatsubara T; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
PLoS One; 2021; 16(4):e0250643. PubMed ID: 33886686
[TBL] [Abstract][Full Text] [Related]
9. The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells.
Zocchi L; Wu SC; Wu J; Hayama KL; Benavente CA
Oncotarget; 2018 May; 9(34):23505-23518. PubMed ID: 29805751
[TBL] [Abstract][Full Text] [Related]
10. Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas.
Osaki S; Tazawa H; Hasei J; Yamakawa Y; Omori T; Sugiu K; Komatsubara T; Fujiwara T; Sasaki T; Kunisada T; Yoshida A; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Sci Rep; 2016 Jun; 6():28953. PubMed ID: 27356624
[TBL] [Abstract][Full Text] [Related]
11. Staurosporine resistance in inflammatory neutrophils is associated with the inhibition of caspase- and proteasome-mediated Mcl-1 degradation.
Hornstein T; Lehmann S; Philipp D; Detmer S; Hoffmann M; Peter C; Wesselborg S; Unfried K; Windolf J; Flohé S; Paunel-Görgülü A
J Leukoc Biol; 2016 Jan; 99(1):163-74. PubMed ID: 26310832
[TBL] [Abstract][Full Text] [Related]
12. Mcl-1 Is a Novel Target of miR-26b That Is Associated with the Apoptosis Induced by TRAIL in HCC Cells.
Jiang C; Long J; Liu B; Xie X; Kuang M
Biomed Res Int; 2015; 2015():572738. PubMed ID: 26078955
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Effects of Myeloid Cell Leukemia-1 siRNA on Human Acute Myeloid Leukemia Cells.
Karami H; Baradaran B; Esfahani A; Sakhinia M; Sakhinia E
Adv Pharm Bull; 2014; 4(3):243-8. PubMed ID: 24754007
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
Pignochino Y; Grignani G; Cavalloni G; Motta M; Tapparo M; Bruno S; Bottos A; Gammaitoni L; Migliardi G; Camussi G; Alberghini M; Torchio B; Ferrari S; Bussolino F; Fagioli F; Picci P; Aglietta M
Mol Cancer; 2009 Dec; 8():118. PubMed ID: 20003259
[TBL] [Abstract][Full Text] [Related]
15. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.
Lestini BJ; Goldsmith KC; Fluchel MN; Liu X; Chen NL; Goyal B; Pawel BR; Hogarty MD
Cancer Biol Ther; 2009 Aug; 8(16):1587-95. PubMed ID: 19556859
[TBL] [Abstract][Full Text] [Related]
16. TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma.
Daigeler A; Brenzel C; Bulut D; Geisler A; Hilgert C; Lehnhardt M; Steinau HU; Flier A; Steinstraesser L; Klein-Hitpass L; Mittelkötter U; Uhl W; Chromik AM
J Exp Clin Cancer Res; 2008 Dec; 27(1):82. PubMed ID: 19077262
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.
Ding Q; Huo L; Yang JY; Xia W; Wei Y; Liao Y; Chang CJ; Yang Y; Lai CC; Lee DF; Yen CJ; Chen YJ; Hsu JM; Kuo HP; Lin CY; Tsai FJ; Li LY; Tsai CH; Hung MC
Cancer Res; 2008 Aug; 68(15):6109-17. PubMed ID: 18676833
[TBL] [Abstract][Full Text] [Related]
18. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
Liu Q; Zhao X; Frissora F; Ma Y; Santhanam R; Jarjoura D; Lehman A; Perrotti D; Chen CS; Dalton JT; Muthusamy N; Byrd JC
Blood; 2008 Jan; 111(1):275-84. PubMed ID: 17761520
[TBL] [Abstract][Full Text] [Related]
19. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization.
Ding Q; He X; Hsu JM; Xia W; Chen CT; Li LY; Lee DF; Liu JC; Zhong Q; Wang X; Hung MC
Mol Cell Biol; 2007 Jun; 27(11):4006-17. PubMed ID: 17387146
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
